Please use this identifier to cite or link to this item: http://hdl.handle.net/10397/111880
PIRA download icon_1.1View/Download Full Text
DC FieldValueLanguage
dc.contributorDepartment of Health Technology and Informatics-
dc.creatorYang, Yen_US
dc.creatorChen, Jen_US
dc.creatorZhou, Jen_US
dc.creatorZhou, Den_US
dc.creatorZhang, Aen_US
dc.creatorJiang, Yen_US
dc.creatorLin, Jen_US
dc.creatorXia, Wen_US
dc.creatorCai, Yen_US
dc.creatorHan, Ren_US
dc.creatorLu, Yen_US
dc.creatorLiu, Den_US
dc.creatorXia, Zen_US
dc.date.accessioned2025-03-18T01:13:22Z-
dc.date.available2025-03-18T01:13:22Z-
dc.identifier.urihttp://hdl.handle.net/10397/111880-
dc.language.isoenen_US
dc.publisherIvyspring Internationalen_US
dc.rights© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.en_US
dc.rightsThe following publication Yang Y, Chen J, Zhou J, Zhou D, Zhang A, Jiang Y, Lin J, Xia W, Cai Y, Han R, Lu Y, Liu D, Xia Z. Connexin43 overexpression promoted ferroptosis and increased myocardial vulnerability to ischemia-reperfusion injury in type 1 diabetic mice. Int J Med Sci 2024; 21(12):2365-2378 is available at https://doi.org/10.7150/ijms.95170.en_US
dc.titleConnexin43 overexpression promoted ferroptosis and increased myocardial vulnerability to ischemia-reperfusion injury in type 1 diabetic miceen_US
dc.typeJournal/Magazine Articleen_US
dc.identifier.spage2365en_US
dc.identifier.epage2378en_US
dc.identifier.volume21en_US
dc.identifier.issue12en_US
dc.identifier.doi10.7150/ijms.95170en_US
dcterms.abstractEnhancement of Connexin43 (Cx43) and ferroptosis are respectively associated with the exacerbation of myocardial ischemia-reperfusion injury (MIRI) in diabetes. Myocardial vulnerability to ischemic insult has been shown to vary during early and later phases of diabetes in experimental settings. Whether or not Connexin43 (Cx43) and ferroptosis interplay during MIRI in diabetes is unknown. We, thus, aimed to investigate whether or not the content of myocardial Cx43 may be attributable to myocardial vulnerability to MIRI at different stages of diabetes and also to explore the potential interplay between Cx43 and ferroptosis in this pathology. Age-matched control and subgroups of Streptozotocin-induced diabetic mice were subjected to MIRI induced by 30 minutes coronary artery occlusion and 2 hours reperfusion respectively at 1, 2 and 5 weeks of diabetes. Rat cardiac H9C2 cells were exposed to high glucose (HG) for 48h in the absence or presence of Cx43 gene knockdown followed by hypoxia/reoxygenation (HR) respectively for 6 and 12 hours. Post-ischemic myocardial infarct size was reduced in 1 and 2 weeks DM mice concomitant with enhanced GPX4 and reduced cardiac Cx43 and ferroptosis as compared to control. By contrast, cardiac GPX4 was significantly reduced while Cx43 increased at DM 5 weeks (D5w) which was correspondent to significant increases in ferroptosis and myocardial infarction. Post-ischemic cardiac function was improved in 1 and 2 weeks but worsened in 5w DM mice as compared with non-diabetic control. GAP19 (Cx43 inhibitor) significantly attenuated ferroptosis and reduced myocardial infarction in D5w mice. Erastin (ferroptosis activator) reversed the cardioprotective effect of GAP19. In vitro, HR significantly reduced cell viability accompanied with reduced GPX4 but elevated Cx43 expression, MDA production and ferroptosis. Cx43 gene knockdown in H9C2 resulted in a significant increase in GPX4, reduction in MDA and ferroptosis, and subsequently reduced post-hypoxic cell viability. The beneficial effects of Cx43 gene knock-down was minified or eliminated by Erastin. It is concluded that Cx43 overexpression exacerbates MIRI under diabetic conditions via promoting ferroptosis, while its down-regulation at early state of diabetes is attributable to enhanced myocardial tolerance to MIRI.-
dcterms.accessRightsopen accessen_US
dcterms.bibliographicCitationInternational Journal of medical sciences, 2024, v. 21, no. 12, p. 2365-2378en_US
dcterms.isPartOfInternational Journal of medical sciencesen_US
dcterms.issued2024-
dc.identifier.scopus2-s2.0-85204683017-
dc.identifier.pmid39310260-
dc.identifier.eissn1449-1907en_US
dc.description.validate202503 bcrc-
dc.description.oaVersion of Recorden_US
dc.identifier.FolderNumberOA_Scopus/WOS, a3900-
dc.identifier.SubFormID51596-
dc.description.fundingSourceRGCen_US
dc.description.fundingSourceOthersen_US
dc.description.fundingTextNational Natural Science Foundation of China; Zhanjiang City science and technology development special fund competitive allocation project; in part by Guangdong Provincial Basic and Applied Basic Science Projecten_US
dc.description.pubStatusPublisheden_US
dc.description.oaCategoryCCen_US
Appears in Collections:Journal/Magazine Article
Files in This Item:
File Description SizeFormat 
v21p2365.pdf7.14 MBAdobe PDFView/Open
Open Access Information
Status open access
File Version Version of Record
Access
View full-text via PolyU eLinks SFX Query
Show simple item record

Page views

4
Citations as of Apr 14, 2025

Downloads

3
Citations as of Apr 14, 2025

SCOPUSTM   
Citations

5
Citations as of Dec 19, 2025

WEB OF SCIENCETM
Citations

4
Citations as of Dec 18, 2025

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.